NeoGenomics (NASDAQ:NEO - Get Free Report) had its price target cut by equities research analysts at BTIG Research from $23.00 to $21.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a "buy" rating on the medical research company's stock. BTIG Research's price target indicates a potential upside of 42.66% from the company's previous close.
A number of other equities analysts have also issued reports on NEO. Benchmark reaffirmed a "buy" rating and set a $18.00 price target on shares of NeoGenomics in a research note on Wednesday. Needham & Company LLC decreased their price target on NeoGenomics from $24.00 to $19.00 and set a "buy" rating for the company in a research note on Tuesday. Piper Sandler raised their price objective on NeoGenomics from $18.00 to $20.00 and gave the stock an "overweight" rating in a research note on Monday, February 26th. William Blair reissued an "outperform" rating on shares of NeoGenomics in a research note on Wednesday, February 21st. Finally, TD Cowen reduced their price objective on NeoGenomics from $21.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $19.78.
Read Our Latest Stock Analysis on NEO
NeoGenomics Stock Performance
NEO stock traded up $0.76 on Thursday, reaching $14.72. The company's stock had a trading volume of 997,580 shares, compared to its average volume of 933,424. NeoGenomics has a 52 week low of $11.03 and a 52 week high of $21.22. The company has a market capitalization of $1.88 billion, a P/E ratio of -22.30 and a beta of 1.12. The firm has a fifty day moving average of $14.95 and a two-hundred day moving average of $15.95. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.48 and a quick ratio of 5.95.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.05. The firm had revenue of $155.55 million during the quarter, compared to analyst estimates of $152.90 million. NeoGenomics had a negative return on equity of 3.54% and a negative net margin of 13.79%. As a group, analysts predict that NeoGenomics will post -0.2 EPS for the current fiscal year.
Insider Activity
In other news, General Counsel Alicia C. Olivo sold 2,587 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total value of $38,701.52. Following the completion of the sale, the general counsel now owns 34,866 shares in the company, valued at $521,595.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.30% of the company's stock.
Institutional Trading of NeoGenomics
Several hedge funds and other institutional investors have recently modified their holdings of the company. Brown Advisory Inc. raised its holdings in NeoGenomics by 16.9% during the fourth quarter. Brown Advisory Inc. now owns 9,643,599 shares of the medical research company's stock valued at $156,033,000 after buying an additional 1,397,397 shares in the last quarter. First Light Asset Management LLC raised its holdings in NeoGenomics by 29.6% during the fourth quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company's stock valued at $63,535,000 after buying an additional 897,843 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in NeoGenomics by 0.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,006,523 shares of the medical research company's stock valued at $48,650,000 after buying an additional 18,603 shares in the last quarter. Schroder Investment Management Group raised its holdings in NeoGenomics by 26.7% during the third quarter. Schroder Investment Management Group now owns 2,513,307 shares of the medical research company's stock valued at $30,914,000 after buying an additional 529,178 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in shares of NeoGenomics by 16.4% in the third quarter. Emerald Advisers LLC now owns 1,927,074 shares of the medical research company's stock valued at $23,703,000 after purchasing an additional 270,855 shares during the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
